Tests ZW251, a new drug, in adults with advanced solid tumors
Tests ZW251 in adults with advanced liver, lung or germ cell cancers.
Plain-language title generated from the registry record
Registry title: A Study of ZW251 in Participants With Advanced Solid Tumors
Key facts
- Where
- Lisbon and Vila Nova de Gaia, PortugalSee the 2 sites
- Phase
- Phase 1
Where in Portugal
- START Lisboa a - Unidade de Ensaios ClÃnicos - Hospital de Santa MariaLisbon, PortugalTaking people
- Unidade Local de Saúde Gaia e EspinhoVila Nova de Gaia, PortugalTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zymeworks BC Inc.
- Trial code
- NCT07164313
- Record updated
- 5 October 2026
- Original description
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).Read full original descriptionShow less
A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).
Inclusion: Pathologically or cytologically confirmed diagnosis of HCC with evidence of locally advanced (unresectable, and ineligible for transplant) and/or metastatic disease. Noninvasive methods may be used to confirm diagnosis; Pathologically or cytologically confirmed diagnosis of squamous cell NSCLC with evidence of locally advanced (unresectable) and/or metastatic disease; Pathologically or cytologically confirmed diagnosis of GCT with evidence of yolk sac and/or choriocarcinoma predominant component and locally advanced (unresectable) and/or metastatic disease; Measurable disease per RECIST v1.1; Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1; Liver function status of Child-Pugh Class A (for HCC only); Adequate organ function.
Exclusion: Known additional malignancy that is progressing or that has required active treatment within the last year; History of hepatic encephalopathy within the past 6 months or requirement for medications to control encephalopathy; Known gastrointestinal bleeding within 3 months; Acute or chronic uncontrolled renal disease, pancreatitis, or non-malignant liver disease; Participants with HCC experiencing main portal vein tumor invasion require sponsor approval for enrollment.